Observational Study to Evaluate the Quality of Life of Healthy Postmenopausal Women Who Take Coenzyme Q-Ubiquinol
NCT ID: NCT03429231
Last Updated: 2018-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2017-11-23
2018-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Funcional Exercise and Supplementation in Perimenopausal Women's Health
NCT07251296
Effect of Cocoa Polyphenols Supplementation on Cardiovascular Risk of Postmenopausal Women
NCT05158673
Polyphenol Metabolism and Personalized Nutrition in Menopause (PolyPause).
NCT07182370
Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause
NCT07112651
Impact of a Probiotic Combination on Quality of Life and Symptoms in Peri- and Postmenopausal Women
NCT06604234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Group
Women who are taking coenzyme Q and who will continue taking it for 3 months
Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol
Patients in the active group will take one tablet a day orally
Control Group
Women who are not taking coenzyme Q and who will not take it in the next 3 months
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol
Patients in the active group will take one tablet a day orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Woman who is taking coenzyme Q-Ubiquinol and who will continue taking at least the next 3 months
* Woman not taking Coenzyme Q-Ubiquinol and not going to take it in the next 3 months
Exclusión Criteria:
* Patients with severe mental illness.
* Suspicion or abuse of alcohol or other drugs during the 12 months prior to the selection
* Any other consideration or finding that, in the opinion of the investigator, considers the non-participation of the subject in the study.
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Santiago Palacios
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Santiago Palacios
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Palacios
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QUbiquinol17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.